NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/23/2026
Back to search
Official data from USPTO
ASCENTAGE PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
04/24/2026
Trademark type
Combined
Nice classes
42
Filing date
03/14/2022
Registration date
11/07/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/07/2023
Last transaction
04/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
CN
Examiner
YARD, JOHN S
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized letter A incorporating a curved band to the left of the stylized wording ASCENTAGE PHARMA.
Holders and representatives
Holders
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Jiangsu Ascentage Pharma Inc.
Representatives
Kathryn E. Smith Wood Herron & Evans LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific and medical research servicesstudies for combined compound functional mechanism on animals; cancer research for medical purposes; pharmaceutical research and developmentearly evaluation for implementation of the new drugs; pharmaceutical research; scientific surveys for medical purposes; chemical analysis services; research and analysis in the field of biochemistry; chemical research service; scientific and medical research services in the nature of chemical analysis assessment service; chemical research and analysis; scientific and medical research services in the nature of chemical synthesis assessment service; chemical analysis; chemistry consulting services; chemical research; cosmetic research; structural and functional analysis of genomes; stem cell research services; biotechnological research; blood analysis service; genetic screening for scientific purposes; biological cloning services; research and development of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research; medical research; pharmaceutical drug development; medical laboratory service; development of pharmaceutical preparations and pharmaceuticals; medical research service; biological research and analysis; bacteriological research; biological research; scientific and medical researchnamely conducting clinical trials for others; computer programming of medical aspects; scientific and technical servicestesting and evaluation of pharmaceuticals; pharmaceutical research
Publications
History of USPTO decisions and trademark events.
39 publications found
CHLD
CHANGE OF OWNER RECEIVED FROM IB
11/07/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/21/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/21/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/21/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/21/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/21/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/21/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/26/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/26/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/26/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/08/2024
FIMP
FINAL DISPOSITION PROCESSED
02/08/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/07/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/31/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/11/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/22/2023
PUBO
PUBLISHED FOR OPPOSITION
08/22/2023
GPNX
NOTIFICATION PROCESSED BY IB
08/21/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/02/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/12/2023
RFNT
REFUSAL PROCESSED BY IB
03/15/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/22/2023
RFRR
REFUSAL PROCESSED BY MPU
02/22/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/27/2022
CNRT
NON-FINAL ACTION WRITTEN
12/26/2022
DOCK
ASSIGNED TO EXAMINER
12/25/2022
MAFR
APPLICATION FILING RECEIPT MAILED
05/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/05/2022
Continuous trademark protection
Get notified about every new filing that threatens ASCENTAGE PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.